Precious Metals

[gfp927z]

Blade, FSTX also has an extremely small float of ~ 1.6 mil shares, though no significant short position (under 1%). But ANVS was like that also, tiny float (4 mil) but only 1% short position, and they ran it up from 5 to 35.

LIFE is another one with a small float (8 mil) and no significant short position (under 1%). This article (below) could explain the recent spike up, and coincides exactly with when the move started (Feb 4th). That suggests the Reddit group isn't involved, unless they are working with Tip Ranks in a coordinated pump, which seems unlikely, but who knows -


>>> 2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon


Tip Ranks

February 4, 2021


https://finance.yahoo.com/news/2-strong-buy-penny-stocks-165357551.html


aTyr Pharma (LIFE)

The next stock we’re looking at, aTyr Pharma, has a focus on inflammatory disease. Its leading drug candidate, ATYR1923, is a Neuropilin-2 (NRP2) agonist, working through the receptor proteins expressed by the NRP2 gene. These pathways are important for cardiovascular development and disease, and play a role in the inflammatory lung disease pulmonary sarcoidosis.

In December, the company reported that the drug candidate had completed enrollment of 36 patients in a Phase 1b/2a clinical trial, testing the drug in the treatment of pulmonary sarcoidosis. Results of the current study are expected in 3Q21, and will inform further trials of ATYR1923, including against other forms of inflammatory lung disease.

On a more immediate note, in early January the company announced top-line results of another Phase 2 clinical involving ATRY1923 – this time in the treatment of patients hospitalized with severe respiratory complications from COVID-19. The results were positive, showing that a single dose of ATYR1923 (at 3 mg/kg) resulted in a 5.5-day median recovery time. Overall, of the patients dosed in this manner, 83% saw recovery in less than one week.

Covering LIFE for Roth Capital, 5-star analyst Zegbeh Jallah noted, “We like the risk profile here, with two shots on goal, and updated data details from the COVID study is expected in the coming months. Also announced recently, is that data from aTyr's Pulmonary Sarcoidosis program, will be reported in 3Q21… the success of either of these studies could result in a doubling or more of the market cap as these opportunities appear to barely be accounted for by investors.”

In line with his optimistic approach, Jallah gives LIFE shares a Buy rating and his $15 price target suggests an impressive 277% potential upside for the coming year. (To watch Jallah’s track record, click here)

Other analysts are on the same page. With 2 additional Buy ratings, the word on the Street is that LIFE is a Strong Buy. On top of this, the average price target is $13.33, suggesting robust growth of ~236% from the current price of $3.97. (See LIFE stock analysis on TipRanks)

<<<